Menu Search
Equities

ALK-Abello A/S

ALK B:CPH

ALK-Abello A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)178.00
  • Today's Change0.00 / 0.00%
  • Shares traded136.65k
  • 1 Year change+117.60%
  • Beta1.1602
Data delayed at least 15 minutes, as of Sep 18 2024 16:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in DKKIncome statement in DKKView more

Year on year ALK-Abello A/S grew revenues 6.94% from 4.51bn to 4.82bn while net income improved 45.07% from 335.00m to 486.00m.
Gross margin63.42%
Net profit margin13.32%
Operating margin17.78%
Return on assets10.22%
Return on equity15.16%
Return on investment12.56%
More ▼

Cash flow in DKKView more

In 2023, ALK-Abello A/S increased its cash reserves by 114.48%, or 253.00m. The company earned 667.00m from its operations for a Cash Flow Margin of 13.83%. In addition the company used 375.00m on investing activities and also paid 31.00m in financing cash flows.
Cash flow per share4.40
Price/Cash flow per share36.27
Book value per share22.22
Tangible book value per share18.65
More ▼

Balance sheet in DKKView more

ALK-Abello A/S has a Debt to Total Capital ratio of 9.34%, a lower figure than the previous year's 10.06%.
Current ratio2.67
Quick ratio1.29
Total debt/total equity0.1031
Total debt/total capital0.0934
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.